| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Jul 14, 2025 | Jul 16, 2025 | Monopar Therapeutics | Director | Sell | 20.0 | -8,904 | -43.67% | ✗ | $356.2K |
| Jun 30, 2024 | Jul 2, 2024 | Monopar Therapeutics | CFO | Sell | 47.5 | -2,998 | -4.96% | ✗ | $2.2K |
| Mar 31, 2024 | Apr 2, 2024 | Monopar Therapeutics | CFO | Sell | 47.5 | -4,082 | -7.48% | ✗ | $2.8K |
| Dec 31, 2023 | Jan 3, 2024 | Monopar Therapeutics | CFO | Sell | 47.5 | -4,578 | -4.92% | ✗ | $1.6K |
| Sep 30, 2023 | Oct 3, 2023 | Monopar Therapeutics | CFO | Sell | 47.5 | -3,444 | -8.31% | ✗ | $2.1K |
| Jun 30, 2023 | Jul 3, 2023 | Monopar Therapeutics | CFO | Sell | 47.5 | -5,104 | -13.95% | ✗ | $4.4K |
| Mar 31, 2023 | Apr 4, 2023 | Monopar Therapeutics | CFO | Sell | 47.5 | -1,842 | -7.81% | ✗ | $2.6K |
| Dec 31, 2022 | Jan 3, 2023 | Monopar Therapeutics | CFO | Sell | 27.5 | -2,569 | -6.61% | ✗ | $6.1K |
| Sep 30, 2022 | Oct 3, 2022 | Monopar Therapeutics | CFO | Sell | 27.5 | -1,753 | -10.60% | ✗ | $2.7K |
| Jun 30, 2022 | Jul 1, 2022 | Monopar Therapeutics | CFO | Sell | 27.5 | -3,083 | -21.19% | ✗ | $7.1K |
| Mar 31, 2022 | Apr 1, 2022 | Monopar Therapeutics | CFO | Sell | 27.5 | -500 | -8.15% | ✗ | $1.3K |
| Jan 1, 2022 | Jan 4, 2022 | Monopar Therapeutics | CFO | Sell | 27.5 | -505 | -9.32% | ✗ | $1.6K |
| Dec 31, 2021 | Jan 4, 2022 | Monopar Therapeutics | CFO | Sell | 27.5 | -501 | -10.68% | ✗ | $1.6K |
| Sep 30, 2021 | Oct 1, 2021 | Monopar Therapeutics | CFO | Sell | 27.5 | -423 | -10.87% | ✗ | $2.1K |
| Jun 30, 2021 | Jul 2, 2021 | Monopar Therapeutics | CFO | Sell | 27.5 | -823 | -23.55% | ✗ | $4.8K |
| Jan 1, 2021 | Jan 5, 2021 | Monopar Therapeutics | CFO | Sell | 27.5 | -504 | -32.39% | ✗ | $3.1K |
| Dec 18, 2019 | Dec 20, 2019 | Monopar Therapeutics | CFO | Buy | 90.0 | +325 | 100.00% | ✗ | $2.6K |